The tide of antimicrobial resistance and selection

International Journal of Antimicrobial Agents

Volumn 34, Issue SUPPL. 3, 2009, Pages

  Wilcox, Mark H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Antibiotic resistance; Carbapenems; Clostridium difficile; Meticillin resistant Staphylococcus aureus; Selection pressure; Tigecycline

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA; KLEBSIELLA PNEUMONIAE INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK ASSESSMENT; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG PRESCRIPTIONS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS; MINOCYCLINE; SELECTION (GENETICS);

EID: 67649958253     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70550-3     Document Type: Article

References (35)

1. Paterson D.L. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38 Suppl 4 (2004) S341-S345
2. EARSS Annual Report 2007. Bilthoven, the Netherlands: European Antimicrobial Resistance Surveillance System; October 2008. http://www.rivm.nl/earss/Images/EARSS%202007_FINAL_tcm61-55933.pdf [accessed 27 April 2009].
3. Schwaber M.J., and Carmeli Y. Carbapenem-resistant enterobacteriaceae: a potential threat. JAMA 300 (2008) 2911-2913
4. Pitout J.D., and Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8 (2008) 159-166
5. Health Protection Agency. Antimicrobial resistance and prescribing in England, Wales and Northern Ireland, 2008 (2008), Health Protection Agency, London. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216798080469 http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216798080469 [accessed 27 April 2009].
6. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14 (2001) 933-951
7. Graffunder E.M., Preston K.E., Evans A.M., and Venezia R.A. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 56 (2005) 139-145
8. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23 (2004) 163-167
9. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296-327
10. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165 (2005) 1430-1435
11. Bratu S., Brooks S., Burney S., Kochar S., Gupta J., Landman D., et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 44 (2007) 972-975
12. Urban C., Bradford P.A., Tuckman M., Segal-Maurer S., Wehbeh W., Grenner L., et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 46 (2008) e127-e130
13. Health Protection Agency. Health Protection Report 3 4 (2009). http://www.hpa.org.uk/hpr/archives/2009/news0409.htm#enterora http://www.hpa.org.uk/hpr/archives/2009/news0409.htm#enterora [accessed 27 April 2009].
14. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 58 (2009) 256-260
15. Wilcox M.H. Antibiotic prescribing as a risk factor for MRSA. Br J Hosp Med 66 (2005) 180-184
16. Tacconelli E., De Angelis G., Cataldo M.A., Pozzi E., and Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61 (2008) 26-38
17. Charbonneau P., Parienti J.J., Thibon P., Ramakers M., Daubin C., du Cheyron D., et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 42 (2006) 778-784
18. Vernaz N., Sax H., Pittet D., Bonnabry P., Schrenzel J., and Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 62 (2008) 601-607
19. Rupnik M., Wilcox M.H., and Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature Med. Forthcoming (2009)
20. Davey P., Brown E., Fenelon L., Finch R., Gould I., Hartman G., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 4 (2005) CD003543.
21. Davey P., Brown E., Fenelon L., Finch R., Gould I., Holmes A., et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 12 (2006) 211-216
22. Settle C.D., Wilcox M.H., Fawley W.N., Corrado O.J., and Hawkey P.M. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin tazobactam. Aliment Pharmacol Ther 12 (1998) 1217-1223
23. Stone S., Kibbler C., How A., and Balstrini A. Feedback is necessary in strategies to reduce hospital acquired infection. BMJ 321 (2000) 302-303
24. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53 (2004) 882-884
25. Freeman J., O'Neill F.J., and Wilcox M.H. Effects of cefotaxime and desacetyl-cefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 52 (2003) 96-102
26. Saxton K., Baines S.D., Freeman J., O'Connor R., and Wilcox M.H. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 53 (2009) 412-420
27. Baines S.D., Freeman J., and Wilcox M.H. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 55 (2005) 974-982
28. Baines S.D., Saxton K., Freeman J., and Wilcox M.H. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 58 (2006) 1062-1065
29. Wilcox M.H. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 13 (2007) 949-952
30. Cooke F.J., and Holmes A.H. The missing care bundle: antibiotic prescribing in hospitals. Int J Antimicrob Agents 30 (2007) 25-29
31. Cao B., Wang H., Sun H., Zhu Y., and Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 57 (2004) 112-118
32. Gerding D.N. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?. Clin Infect Dis 25 Suppl (1997) S206-S210
33. Padiglione A.A., Wolfe R., Grabsch E.A., Olden D., Pearson S., Franklin C., et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 47 (2003) 2492-2498
34. Carsenti-Etesse H., Cavallo J.D., Roger P.M., Ziha-Zarifi I., Plesiat P., Garrabé E., et al. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 7 (2001) 144-151
35. Carmeli Y., Eliopoulos G.M., and Samore M.H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 8 (2002) 802-807